clinical trial · NCT06315491
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Platinum-resistant Ovarian CancerRefractory Ovarian CarcinomaCBX-12
brief summary
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
started
Sep 25, 2024
primary completion
Oct 1, 2025
completion
Oct 1, 2025
last updated
Oct 6, 2025
official title
A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol